Remarkably, treatment with Tegavivint significantly impeded tumor formation in CDH4-overexpressing TPC-1 cells (Fig. 7C), and it also significantly reduced the volume and weight of tumors compared to both control and CDH4-overexpressing groups (Fig. 7D, E). This evidence concerns the gene CDH4 and neoplasm.